The Business Times
SUBSCRIBERS

Medtech startup set to revolutionise cancer diagnostics

    Published Wed, Jan 21, 2015 · 09:50 PM

    Singapore

    A SINGAPORE-based medtech startup that is looking to bring low-cost, simple-to-use cancer diagnostics tests to the masses, is set to revolutionise the global cancer diagnostics market that is projected to hit some US$168.6 billion in 2020.

    VolitionRx has developed a blood-based - therefore non-invasive - test platform that can potentially diagnose a wide range of cancers including colorectal and prostate, two of the most common cancers affecting men and women globally, The Business Times has learnt.

    Startups

    Copyright SPH Media. All rights reserved.

    Reuse this contentFeedback
    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More